Shots:

• The company resumes the P-III program (explorer6- 7- and 8) of concizumab. The clinical trials are evaluating concizumab (SC) prophylaxis treatment in hemophilia A and B patients regardless of their inhibitor status
• The trials will be resumed as soon as local procedures allow. This follows pausing of the trials in Mar’20 due to the occurrence of non-fatal thrombotic events in 3 patients enrolled in the ongoing P-III program
• In Oct 2019- Novo Nordisk has initiated the explorer7 study to establish the safety and efficacy of concizumab (SC- qd) delivered in a pen device to reduce the number of bleeds in patients with hemophilia A or B with inhibitors towards FVIII/ FIX. In Nov 2019- the company initiated P-III explorer8 study in hemophilia A or B patients without inhibitors. The trials are to enroll ~293 patients across 32 countries

­ Ref: Novo Nordisk  | Image: Scrip Informa